DE69739423D1 - Verwendung von onkofötal-antigen spezifischen cd4, cd8 zytotoxischen, suppressor t-zellen und interleukin-10 - Google Patents

Verwendung von onkofötal-antigen spezifischen cd4, cd8 zytotoxischen, suppressor t-zellen und interleukin-10

Info

Publication number
DE69739423D1
DE69739423D1 DE69739423T DE69739423T DE69739423D1 DE 69739423 D1 DE69739423 D1 DE 69739423D1 DE 69739423 T DE69739423 T DE 69739423T DE 69739423 T DE69739423 T DE 69739423T DE 69739423 D1 DE69739423 D1 DE 69739423D1
Authority
DE
Germany
Prior art keywords
cells
individual
tumor
onkofötal
suppressor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739423T
Other languages
English (en)
Inventor
Joseph H Coggin
Adel L Barsoum
James W Rohrer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Alabama
South Alabama Medical Science Foundation
Original Assignee
University of South Alabama
South Alabama Medical Science Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Alabama, South Alabama Medical Science Foundation filed Critical University of South Alabama
Application granted granted Critical
Publication of DE69739423D1 publication Critical patent/DE69739423D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57476—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofetal proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69739423T 1996-04-05 1997-04-04 Verwendung von onkofötal-antigen spezifischen cd4, cd8 zytotoxischen, suppressor t-zellen und interleukin-10 Expired - Lifetime DE69739423D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1490396P 1996-04-05 1996-04-05
PCT/US1997/005685 WO1997038089A1 (en) 1996-04-05 1997-04-04 Uses of oncofetal antigen specific cd4, cd8 cytotoxic and suppressor t cells and interleukin-10

Publications (1)

Publication Number Publication Date
DE69739423D1 true DE69739423D1 (de) 2009-07-09

Family

ID=21768461

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739423T Expired - Lifetime DE69739423D1 (de) 1996-04-05 1997-04-04 Verwendung von onkofötal-antigen spezifischen cd4, cd8 zytotoxischen, suppressor t-zellen und interleukin-10

Country Status (7)

Country Link
US (2) US6335174B1 (de)
EP (1) EP0939796B1 (de)
AT (1) ATE432339T1 (de)
AU (1) AU2723597A (de)
CA (1) CA2250164C (de)
DE (1) DE69739423D1 (de)
WO (1) WO1997038089A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718762B2 (en) 2002-08-02 2010-05-18 South Alabama Medical Science Foundation Cancer vaccines containing epitopes of oncofetal antigen
EP1444989A1 (de) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisierung von Zellen für die Apoptose durch selektive Blockade von Zytokinen
BRPI0915582A2 (pt) * 2008-06-06 2016-01-26 Baylor Res Inst anticorpos anto-cd8 que bloqueiam a sensibilização de efetores citotóxicos e levam à geração de células t cd8+ reguladoras
CA3070297A1 (en) 2017-08-11 2019-02-14 Genentech, Inc. Anti-cd8 antibodies and uses thereof
WO2024097864A1 (en) * 2022-11-02 2024-05-10 Tigen Pharma Sa Expansion of lymphocytes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610878A (en) * 1983-06-16 1986-09-09 Medical University Of South Carolina Use of in vitro assay techniques to measure parameters related to clinical applications of transfer factor therapy
US4746539A (en) 1983-11-23 1988-05-24 The Ohio State University Research Foundation Purification of cancer-associated protein and preparation of antibody thereto
US4686180A (en) 1984-11-21 1987-08-11 South Alabama Medical Science Foundation Onco-fetal specific monoclonal antibodies, methods of preparation and use
US5180809A (en) 1988-05-20 1993-01-19 La Jolla Cancer Research Foundation Adhesion receptor for laminin and its use
US5525461A (en) * 1991-11-01 1996-06-11 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using total leukocyte surface antigens
US5532159A (en) 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer

Also Published As

Publication number Publication date
CA2250164A1 (en) 1997-10-16
EP0939796A1 (de) 1999-09-08
EP0939796B1 (de) 2009-05-27
US6534060B1 (en) 2003-03-18
WO1997038089A1 (en) 1997-10-16
EP0939796A4 (de) 2004-10-20
CA2250164C (en) 2011-12-06
ATE432339T1 (de) 2009-06-15
AU2723597A (en) 1997-10-29
US6335174B1 (en) 2002-01-01

Similar Documents

Publication Publication Date Title
MY111196A (en) Therapeutic aplication of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
HK1026144A1 (en) Aryl ureas for the treatment of inflammatory or immunomodulatory diseases.
HU9302484D0 (en) Dissoluble ligands for cd-40
ZA91559B (en) Vaccines against cancer and infectious diseases
KR970704410A (ko) 암 치료용 종양 세포를 함유하는 이식 장치(Implanted Device Containing Tumor Cells for the Treatment of Cancer)
KR890700401A (ko) 석탄 분쇄기용 불활성화 및 소화시스템
GB9002957D0 (en) Probe,and method of use thereof for biomodulation of tissue,nerve and immune systems
AU7813191A (en) Novel immunoconjugates and methods for their use in tumor therapy
GB8312221D0 (en) Human tissue plasminogen activator
EP0260610A3 (en) Monoclonal antibodies against human tumour necrotic factor (tnf), and their use
DE3583392D1 (de) Carbonatapatit enthaltendes mittel und die verwendung von carbonatapatit fuer implantate.
DE69733610D1 (de) Interleukin-15 antagoniste
EP0928175A4 (de) Thermotherapie
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
HUP0001316A3 (en) Method for the detection and localization of malignant human tumours
AU7242796A (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
AU6786887A (en) Tumor localization and therapy
DE69739423D1 (de) Verwendung von onkofötal-antigen spezifischen cd4, cd8 zytotoxischen, suppressor t-zellen und interleukin-10
EP0553294A4 (en) Methods and compositions for the treatment of cell proliferation disorders
ZA892275B (en) Combination therapy of il-2 and dtic for the treatment of melanoma
NZ217331A (en) Tissue plasminogen activator derivatives and genetically engineered product
IT8123773A0 (it) Procedimento e apparecchiatura per la riduzione gassosa di minerale di ferro in ferro spugnoso.
GB2189144B (en) Zinc complex of 5-chloro-7-iodo-8hydroxyquinoline having antimycotic activity and therapeutic use thereof.
GEP20012489B (en) Use of Natural Human α-Interferon
DE59712247D1 (de) Mammakarzinom-assoziiertes gen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R079 Amendment of ipc main class

Ref document number: 939796

Country of ref document: EP

Free format text: PREVIOUS MAIN CLASS: C12N0005000000

Ipc: C12N0005078300